Drugs / 99mTc-NTP 15-5
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04481230 | Nov 2020 → Jul 2022 | breast cancer, osteoarthritis, knee | Centre Jean Perrin | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07624994 | Aug 2026 → Jul 2028 expected | arthritic joint disease | Centre Jean Perrin | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 99mTc-NTP 15-5 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07624994 ↗ |
| Modality | Diagnostic / imaging agent | “99mTc-NTP 15-5 is a SPECT radiotracer” PMID 36314021 ↗ Oct 2022 |
| Route | Intravenous | “1 intravenous injection” NCT04481230 ↗ |